Pirker Robert, Lehnert Martina, Minar Wilma
Department of Internal Medicine I, Medical University Vienna, Währinger Gürtel 18, A-1090 Vienna, Austria.
Lung Cancer. 2007 Jan;55(1):89-94. doi: 10.1016/j.lungcan.2006.09.020. Epub 2006 Nov 3.
Anemia occurs frequently in patients with lung cancer receiving chemotherapy and has a negative impact on quality of life (QoL). Erythropoietic proteins effectively increase hemoglobin (Hb) levels, reduce transfusion requirements and improve QoL in anemic patients with a range of malignancies. This prospective, observational study evaluated epoetin beta 30,000 IU once weekly in patients with lung cancer in a real-life, clinical-practice setting. Forty patients (72.5% with NSCLC and 27.5% with SCLC) were treated with epoetin beta during any cycle of chemotherapy when Hb decreased to <12 g/dL. Hb levels were assessed at regular intervals and transfusion needs were monitored throughout the study. In total, 72.5% of patients required epoetin treatment by the second cycle of chemotherapy. Epoetin beta treatment duration ranged from 1 to >9 (median 4) weeks. Mean (+/-S.D.) baseline Hb was 10.4+/-1.2 g/dL. Epoetin beta was associated with a rapid increase in Hb levels, with a mean increase of 1.3 g/dL by week 4. Most patients (95%) remained transfusion-free throughout the study. Epoetin beta was well tolerated. This early intervention strategy with epoetin beta 30,000 IU once weekly is an effective and well-tolerated therapy for anemia in patients with lung cancer.
贫血在接受化疗的肺癌患者中经常出现，并且会对生活质量（QoL）产生负面影响。促红细胞生成蛋白能有效提高血红蛋白（Hb）水平，减少输血需求，并改善患有一系列恶性肿瘤的贫血患者的生活质量。这项前瞻性观察性研究在现实生活的临床实践环境中，评估了每周一次给予肺癌患者30,000国际单位促红细胞生成素β的效果。40例患者（72.5%为非小细胞肺癌，27.5%为小细胞肺癌）在化疗的任何周期中，当Hb降至<12 g/dL时接受促红细胞生成素β治疗。在整个研究过程中定期评估Hb水平，并监测输血需求。总共有72.5%的患者在化疗的第二个周期需要促红细胞生成素治疗。促红细胞生成素β的治疗持续时间为1至>9周（中位数为4周）。平均（±标准差）基线Hb为10.4±1.2 g/dL。促红细胞生成素β与Hb水平的快速升高相关，到第4周时平均升高1.3 g/dL。在整个研究过程中，大多数患者（95%）无需输血。促红细胞生成素β耐受性良好。这种每周一次给予30,000国际单位促红细胞生成素β的早期干预策略，是治疗肺癌患者贫血的一种有效且耐受性良好的疗法。
